Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole - PubMed (original) (raw)

Clinical Trial

Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole

Kari Raaska et al. Clin Pharmacol Ther. 2002 Oct.

Abstract

Objective: Our objective was to examine the effects of itraconazole on the pharmacokinetics and cortisol-suppressant activity of budesonide administered by inhalation.

Methods: In a randomized, double-blind, 2-phase crossover study, 10 healthy subjects took 200 mg itraconazole or placebo orally once a day for 5 days. On day 5, 1 hour after the last dose of itraconazole or placebo, 1000 microg budesonide was administered by inhalation. Plasma budesonide and cortisol concentrations were measured up to 23 hours.

Results: Itraconazole increased the mean total area under the plasma concentration-time curve of inhaled budesonide 4.2-fold (range, 1.7-fold to 9.8-fold; P <.01) and the peak plasma concentration 1.6-fold (P <.01) compared with placebo. The mean terminal half-life of budesonide was prolonged from 1.6 to 6.2 hours (ie, 3.7-fold; range, 1.5-fold to 9.3-fold; P <.001) by itraconazole. The suppression of cortisol production after inhalation of budesonide was significantly increased by itraconazole as compared with placebo, as shown by a 43% reduction in the area under the plasma cortisol concentration-time curve from 0.5 to 10 hours (P <.001) and a 12% decrease in the cortisol concentration measured 23 hours after administration of budesonide, at 8 am (P <.05).

Conclusions: Itraconazole markedly increased systemic exposure to inhaled budesonide, probably by inhibiting the cytochrome P4503A4-mediated metabolism of budesonide during both the first-pass and the elimination phases. This interaction resulted in enhanced systemic effects of budesonide, as shown by suppression of cortisol production. Long-term coadministration of budesonide and a potent CYP3A4 inhibitor may be associated with an increased risk of adverse effects of budesonide.

PubMed Disclaimer

Cited by

Cushing's syndrome without excess cortisol.
Woods DR, Arun CS, Corris PA, Perros P. Woods DR, et al. BMJ. 2006 Feb 25;332(7539):469-70. doi: 10.1136/bmj.332.7539.469. BMJ. 2006. PMID: 16497762 Free PMC article. No abstract available.
A compartment-quasi-3D multiscale approach for drug absorption, transport, and retention in the human lungs.
Kannan RR, Singh N, Przekwas A. Kannan RR, et al. Int J Numer Method Biomed Eng. 2018 May;34(5):e2955. doi: 10.1002/cnm.2955. Epub 2018 Jan 25. Int J Numer Method Biomed Eng. 2018. PMID: 29272565 Free PMC article.
The role of antifungals in the management of patients with severe asthma.
Rapeport WG, Ito K, Denning DW. Rapeport WG, et al. Clin Transl Allergy. 2020 Nov 6;10(1):46. doi: 10.1186/s13601-020-00353-8. Clin Transl Allergy. 2020. PMID: 33292524 Free PMC article. Review.
Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide.
Böhmer GM, Drollmann A, Gleiter CH, Nave R. Böhmer GM, et al. Clin Pharmacokinet. 2008;47(5):343-9. doi: 10.2165/00003088-200847050-00005. Clin Pharmacokinet. 2008. PMID: 18399715 Clinical Trial.
Budesonide/formoterol: in chronic obstructive pulmonary disease.
Reynolds NA, Perry CM, Keating GM. Reynolds NA, et al. Drugs. 2004;64(4):431-41; discussion 433-4. doi: 10.2165/00003495-200464040-00006. Drugs. 2004. PMID: 14969576 Review.

Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole - PubMed (original) (raw)